A clinical study of drug Eranda for the treatment in patients of Aamvata and Vatarakta
Phase 2
- Conditions
- Health Condition 1: M241- Other articular cartilage disorders
- Registration Number
- CTRI/2022/07/043885
- Lead Sponsor
- Government Ayurvedic College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients with written consent, 2.Having clinical features of Amavata or Vatarakta, 3.Patients fulfilling subjective and objective criteria like sandhi shool, shotha, sandhi stabhdhata etc. in amavata and Sandhi graha, twaka vaivrnaya, raga etc. in vatarakta
Exclusion Criteria
1.Patients below 30 and above 70 years of age
2. Pregnant and lactating mothers
3. Patients with serious systemic illness
4. Patients with complications of Amavata and Vatarakta
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Subjective Parameter- Grading will be done with signs and symptoms of both Amavata and Vatarakta respectively. <br/ ><br>RA Factor, CRP, ESR for Amavata and Uric Acid levels for VataraktaTimepoint: After one month intervention of Erandamool kwatha orally and 15 days after stopping of medicine <br/ ><br>
- Secondary Outcome Measures
Name Time Method Subjective Parameter- Grading will be done with signs and symptoms of both Amavata and Vatarakta respectively. <br/ ><br>RA Factor, CRP, ESR for Amavata and Uric Acid levels for Vatarakta.Timepoint: After one month intervention of erandamool Kwatha orally, and 15 days after stopping of medicine.